RAMPs: 5 Years on, where to now?

Trends in Pharmacological Sciences

Volumn 24, Issue 11, 2003, Pages 596-601

  Morfis, Maria ^a   Christopoulos, Arthur ^a   Sexton, Patrick M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; N [2 [[5 AMINO 1 [[4 (4 PYRIDINYL) 1 PIPERAZINYL]CARBONYL]PENTYL]AMINO] 1 [(3,5 DIBROMO 4 HYDROXYPHENYL)METHYL] 2 OXOETHYL] 4 (1,4 DIHYDRO 2 OXO 3(2H) QUINAZOLINYL) 1 PIPERIDINECARBOXAMIDE; QUINAZOLINE DERIVATIVE; RECEPTOR ACTIVITY MODIFYING PROTEIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; MIGRAINE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW;

EID: 0242352554     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.09.001     Document Type: Review

References (55)

1. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:2002;323-374.
2. McLatchie L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 393:1998;333-339.
3. Sexton P.M., et al. Receptor activity modifying proteins. Cell. Signal. 13:2001;73-82.
4. Born W., et al. Receptors for calcitonin gene-related peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity- modifying proteins. Receptors Channels. 8:2002;201-209.
5. Poyner D.R., et al. The mammalian CGRP, adrenomedullin, amylin and calcitonin receptors. Pharmacol. Rev. 54:2002;233-246.
6. Chrisopoulos G., et al. Multiple amylin receptor phenotypes arise from RAMP interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56:1999;235-242.
7. Muff R., et al. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology. 140:1999;2924-2927.
8. Tilakaratne N., et al. Amylin receptor phenotypes derived from human calcitonin receptor /RAMP co-expression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J. Pharmacol. Exp. Ther. 294:2000;61-72.
9. Zumpe E.T., et al. Multiple RAMP domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem. Biophys. Res. Commun. 267:2000;368-372.
10. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs. 15:2001;745-753.
11. Salmon A.M., et al. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat. Neurosci. 4:2001;357-358.
12. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1:2002;198-210.
13. Aiyar N., et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J. Pharmacol. Exp. Ther. 296:2001;768-775.
14. Doods H., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129:2000;420-442.
15. Mallee J.J., et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277:2002;14294-14298.
16. Leuthauser K., et al. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. Biochem. J. 351:2000;347-351.
17. Kuwasako K., et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J. Biol. Chem. 275:2000;29602-29609.
18. Hilairet S., et al. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J. Biol. Chem. 276:2001;29575-29581.
19. Hilairet S., et al. Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J. Biol. Chem. 276:2001;42182-42190.
20. Aldecoa A., et al. Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells. FEBS Lett. 471:2000;156-160.
21. Fraser N.J., et al. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol. Pharmacol. 55:1999;1054-1059.
22. Fitzsimmons T.J., et al. The extracellular domain of receptor activity-modifying protein 1 (RAMP1) is sufficient for calcitonin receptor-like receptor (CRLR) function. J. Biol. Chem. 278:2003;14313-14320.
23. Steiner S., et al. The transmembrane domain of receptor-activity- modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry. 41:2002;11398-11404.
24. Kuwasako K., et al. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J. Biol. Chem. 278:2003;22623-22630.
25. Kuwasako K., et al. The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors. J. Biol. Chem. 276:2001;49459-49465.
26. Evans B.N., et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 275:2000;31438-31443.
27. Prado M.A., et al. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides. 22:2001;1773-1781.
28. Sexton P.M. Recent advances in our understanding of peptide hormone receptors and RAMPs. Curr. Opin. Drug Discov. Dev. 2:1999;440-448.
29. Christopoulos A., et al. Novel receptor partners and function of receptor activity modifying proteins. J. Biol. Chem. 278:2003;3293-3297.
30. Husmann K., et al. Mouse receptor activity modifying proteins 1, -2 and -3: Amino acid sequence, expression and function. Mol. Cell. Endocrinol. 162:2000;35-43.
31. Buhlmann N., et al. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology. 140:1999;2883-2890.
32. Christopoulos A., El-Fakahany E.E. Qualitative and quantitative determination of relative agonist efficacy. Biochem. Pharmacol. 58:1999;735-748.
33. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1:2002;103-110.
34. Chakravarty P., et al. CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues. Br. J. Pharmacol. 130:2000;189-195.
35. Choksi T., et al. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br. J. Pharmacol. 136:2002;784-792.
36. Fukai N., et al. Coexpression of calcitonin receptor-like receptor and receptor activity-modifying protein 2 or 3 mediates the antimigratory effect of adrenomedullin. Endocrinology. 144:2003;447-453.
37. Oliver K.R., et al. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J. Cereb. Blood Flow Metab. 22:2002;620-629.
38. Basille M., et al. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J. Comp. Neurol. 425:2000;495-509.
39. Oliver K.R., et al. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur. J. Neurosci. 14:2001;618-628.
40. Usdin T.B., et al. The parathyroid hormone 2 (PTH2) receptor. Receptors Channels. 8:2002;211-218.
41. Caron K.M., Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc. Natl. Acad. Sci. U. S. A. 98:2001;615-619.
42. Shindo T., et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation. 104:2001;1964-1971.
43. Totsune K., et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin. Sci. (Lond.). 99:2000;541-546.
44. Nishikimi T., et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension. 41:2003;512-518.
45. Qi T.F., et al. Changes of adrenomedullin and receptor activity modifying protein 2 (RAMP2) in myocardium and aorta in rats with isoproterenol-induced myocardial ischemia. Peptides. 24:2003;463-468.
46. Wang X., et al. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. J. Hypertens. 21:2003;1171-1181.
47. Cueille C., et al. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. Biochem. Biophys. Res. Commun. 294:2002;340-346.
48. Mishima K., et al. Effects of endothelin on adrenomedullin secretion and expression of adrenomedullin receptors in rat cardiomyocytes. Biochem. Biophys. Res. Commun. 287:2001;264-269.
49. Mishima K., et al. Angiotensin II modulates gene expression of adrenomedullin receptor components in rat cardiomyocytes. Life Sci. 73:2003;1629-1635.
50. Dong Y.L., et al. Expression of calcitonin gene-related peptide receptor components, calcitonin receptor-like receptor and receptor activity modifying protein 1, in the rat placenta during pregnancy and their cellular localization. Mol. Hum. Reprod. 9:2003;481-490.
51. Thota, C. et al. Changes in the expression of CRLR, RAMP1, RAMP2 and RAMP3 in rat uterus during pregnancy, labor, and by steroid hormone treatments. Biol. Reprod. (in press) 10.1095/biolreprod.103.015628.
52. Frayon S., et al. Dexamethasone increases RAMP1 and CRLR mRNA expressions in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 270:2000;1063-1067.
53. Nagae T., et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem. Biophys. Res. Commun. 270:2000;89-93.
54. Ono Y., et al. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochem. Biophys. Res. Commun. 271:2000;197-202.
55. Kuwasako K., et al. Rat RAMP domains involved in adrenomedullin binding specificity. FEBS Lett. 519:2002;113-116.